companiesCompany
Catalent (Novo Holdings)
Major fill-finish and gene-therapy CDMO, acquired by Novo Holdings in 2024 with three sites transferred to Novo Nordisk.
Sterile injectables, biologics, and cell/gene therapy manufacturing; capacity shifts after the Novo deal affected some oncology sponsors.